Related Experiment Videos
Cost-utility analysis of pacemakers for the treatment of vasovagal syncope
C R Mitton1, M S Rose, M L Koshman
1Health Research Group, University of Calgary, Alberta, Canada.
The American Journal of Cardiology
|December 30, 1999
Abstract:
Dual-chamber pacing is a promising treatment for patients with very frequent vasovagal syncope, but its cost utility is unknown. We report that the incremental cost per quality-adjusted life-year gained is $13,159 Canadian dollars (about $8,600 US dollars), and therefore this pacemaker therapy for vasovagal syncope has a favorable cost-utility ratio.